197636-95-6

Basic information

• Product Name: N-(N'-tert-butyloxycarbonylethanediamino)-2,3-bis(benzyloxy)benzamide
• Synonyms: N-(N'-tert-butyloxycarbonylethanediamino)-2,3-bis(benzyloxy)benzamide
• CAS NO: 197636-95-6
• Molecular Weight: 476.572
• Mol File: 197636-95-6.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: N-(N'-tert-butyloxycarbonylethanediamino)-2,3-bis(benzyloxy)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(N'-tert-butyloxycarbonylethanediamino)-2,3-bis(benzyloxy)benzamide(197636-95-6)
• EPA Substance Registry System: N-(N'-tert-butyloxycarbonylethanediamino)-2,3-bis(benzyloxy)benzamide(197636-95-6)

Safety Data

• Hazardous Substances Data: 197636-95-6(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 74272-78-9 2,3-dibenzyloxybenzoic acid 
• 107-15-3 ethylenediamine 
• 100-39-0 benzyl bromide 
• 57260-73-8 N-BOC-1,2-diaminoethane 
• 303-38-8 2,3-Dihydroxybenzoic acid 
• 95922-26-2 benzyl 2,3-bis(benzyloxy)benzoate 
• 69146-58-3 2,3-bis(benzyloxy)benzoyl chloride 

Relevant articles and documents

Formation of a tris(catecholato) iron(iii) complex with a nature-inspired cyclic peptoid ligand

Siderophore-mimicking macrocyclic peptoids were synthesized. Peptoid3with intramolecular hydrogen bonds showed an optimally arranged primary coordination sphere leading to a stable catecholate-iron complex. The tris(catecholato) structure of 3-Fe(iii) was determined with UV-vis, fluorescence, and EPR spectroscopies and DFT calculations. The iron binding affinity was comparable to that of deferoxamine, with enhanced stability upon air exposure.

Peptoid-based siderophore mimics as dinuclear Fe3+chelators

A practical synthesis of preorganized tripodal enterobactin/corynebactin-type ligands (consisting of aC3-symmetric macrocyclic peptoid core, three catecholamide coordinating units, and C2, C4, and C6spacers) is

1,4,7,10-TETRAZACYCLODODECANE BASED AGENTS TO TARGET BACTERIA AND ITS USE

The present invention relates to new compounds comprising a siderophore moiety as well as a core structure able to chelate a metal ion. Optionally, the compounds may have additionally a moiety with a functional element including a marker molecule, a bioactive agent, an activity based probe suitable to monitor the aberrant expression or activity of proteins involved in the initiation and progression of bacterial infection, or a compound useful for bacterial inhibition. In a further aspect, the present invention provides a pharmaceutical composition containing said compound, for example, said pharmaceutical composition is an antibiotic. Additionally, the present invention relates to the use of said compounds in diagnostic methods, in particular, imaging methods including SPEC, PET or MRI. In an embodiment of the present invention, the compound is part of a theranostic composition having both, therapeutic as well as diagnostic activities.